8.32

1.07% -0.09

After Hours: 8.41 0.09 +1.08%

Amneal Pharmaceuticals Inc (AMRX)

Overview News Price History Option Chain Discussions Forecast

Amneal Pharmaceuticals Inc stock is traded at $8.32, with a volume of 779.14K. It is down -1.07% in the last 24 hours and down -1.77% over the past month. Amneal Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations. It is also involved in the development, manufacture, and sale of branded pharmaceutical products primarily for central nervous system disorders and parasitic infections; and biosimilar products. In addition, the company offers licensed and owned, niche, and mature branded products, as well as a pipeline of 505(b)(2) products for various therapeutic areas that primarily includes Unithroid for endocrinologists and primary care physicians through a contracted salesforce. Amneal Pharmaceuticals, Inc. has a partnership agreement with MabXience S.L. for the development of Avastin, a biosimilar bevacizumab. The company has operations in North America, Asia, and Europe. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Previous Close:

$8.41

Open:

$8.4

24h Volume:

779.14K

Relative Volume:

0.71

Market Cap:

$2.58B

Revenue:

$2.50B

Net Income/Loss:

$-168.69M

P/E Ratio:

-416.00

EPS:

-0.02

Net Cash Flow:

$124.24M

1W Performance:

-7.56%

1M Performance:

-1.77%

6M Performance:

+24.36%

1Y Performance:

+86.13%

1-Day Range:

$8.28

$8.4743

1-Week Range:

$8.11

$9.01

52-Week Range:

$4.16

$9.475

Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile

Name

Amneal Pharmaceuticals Inc

Sector

Healthcare (1195)

Industry

Drug Manufacturers - Specialty & Generic (87)

Phone

908-947-3120

Address

400 Crossing Boulevard, 3rd Floor, Bridgewater

Employee

5,210

Twitter

@amnealpharma

Next Earnings Date

2024-12-08

Latest SEC Filings

AMRX's Discussions on Twitter

Compare AMRX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AMRX	8.32	2.58B	2.50B	-168.69M	124.24M	-0.02
ZTS	176.71	79.55B	9.15B	2.43B	2.31B	4.92
HLN	9.55	43.18B	14.26B	1.55B	0	0.3327
TAK	13.33	42.26B	30.27B	1.93B	3.45B	0.444
TEVA	17.08	19.35B	16.77B	-959.00M	1.37B	-2.00
VTRS	13.25	15.77B	15.24B	-646.50M	1.88B	1.53

Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-07-21	Resumed	RBC Capital Mkts	Sector Perform
Mar-08-21	Upgrade	Goldman	Sell → Buy
Dec-14-20	Upgrade	Barclays	Equal Weight → Overweight
Dec-14-20	Upgrade	Guggenheim	Neutral → Buy
Jul-27-20	Initiated	Goldman	Sell
May-12-20	Upgrade	Guggenheim	Sell → Neutral
Dec-12-19	Downgrade	Raymond James	Outperform → Mkt Perform
Nov-12-19	Downgrade	JP Morgan	Neutral → Underweight
Nov-07-19	Downgrade	SVB Leerink	Outperform → Mkt Perform
Jul-22-19	Upgrade	SVB Leerink	Mkt Perform → Outperform
Jul-11-19	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Jul-08-19	Upgrade	Piper Jaffray	Neutral → Overweight
Jun-11-19	Initiated	Barclays	Equal Weight
May-21-19	Upgrade	Raymond James	Mkt Perform → Strong Buy
Mar-20-19	Initiated	SunTrust	Buy
Mar-08-19	Downgrade	SVB Leerink	Outperform → Mkt Perform
Dec-14-18	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Oct-16-18	Downgrade	SunTrust	Buy → Hold
Aug-13-18	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Jul-23-18	Initiated	Morgan Stanley	Overweight
Jun-22-18	Initiated	B. Riley FBR, Inc.	Buy

View All

Amneal Pharmaceuticals Inc Stock (AMRX) Latest News

05:05 AM

Amneal Resubmits New Drug Application for Migraine Treatment, Diabetes Drug Is Approved - MarketWatch

05:05 AM

04:34 AM

Amneal resubmits migraine autoinjector NDA, receives FDA nod for exenatide - Investing.com

04:34 AM

04:05 AM

Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist - Yahoo Finance

04:05 AM

05:49 AM

GSA Capital Partners LLP Sells 100,410 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat

05:49 AM

05:40 AM

Senior VP Of Amneal Pharmaceuticals Sold 76% Of Their Shares - Simply Wall St

05:40 AM

Nov 20, 2024

Amneal Pharmaceuticals Q3 2024 Earnings Preview - MSN

Nov 20, 2024